Basilea Pharmaceutica AG Share Price
Stocks
BSLN
CH0011432447
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Swiss Exchange
09:01:39 21/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 69.00 CHF | 0.00% |
|
+4.39% | +26.14% |
| 14/09 | Japanese Stocks Fall on AI Development Slowdown Calls; Oil Gains | MT |
| 14/09 | Asahi Kasei Unit Starts Phase Two Study of Antifungal Cresemba for Pediatric Patients in Japan | MT |
| Market Cap | 86Cr 104.34Cr 91Cr 78Cr 146.31Cr 10TCr 146.49Cr 1.03TCr 395.51Cr 5.09TCr 391.95Cr 383.26Cr 16TCr | P/E 2026 * |
16x | P/E 2027 * | 17.9x |
|---|---|---|---|---|---|
| Enterprise Value | 70Cr 86Cr 75Cr 64Cr 120.23Cr 8.21TCr 120.38Cr 843.3Cr 325.03Cr 4.18TCr 322.1Cr 314.96Cr 14TCr | EV / Sales 2026 * |
2.63x | EV / Sales 2027 * | 2.32x |
| Free-Float |
91.74% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Swiss Exchange
| BSLN | Delayed | |
CBOE
| 0QNA | Real-time | |
|
London S.E.
| 0QNA | Delayed | |
|
Boerse Muenchen
| PK5 | Real-time | |
|
OTC Markets
| BPMUF | Delayed | |
|
Tradegate
| PK5 | Real-time | |
|
Deutsche Boerse AG
| PK5 | Delayed | |
|
Börse Stuttgart
| PK5 | Delayed |
Last Transcript: Basilea Pharmaceutica AG
| 1 day | +0.80% | ||
| 1 week | +4.39% | ||
| Current month | +8.66% | ||
| 1 month | +6.81% | ||
| 3 months | +35.56% | ||
| 6 months | +33.98% | ||
| Current year | +26.14% |
| 1 week | 64.8 |  | 70.5 |
| 1 month | 62.2 | | 70.5 |
| Current year | 47.8 | | 70.5 |
| 1 year | 44.7 | | 70.5 |
| 3 years | 32 | | 70.5 |
| 5 years | 29.55 | | 70.5 |
| 10 years | 29.28 | | 95.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 61 | 19/04/2018 |
Adesh Kaul
DFI | Director of Finance/CFO | 52 | 10/04/2019 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 62 | 01/05/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Werner
BRD | Director/Board Member | 70 | 29/11/2011 |
| Chairman | 71 | 09/04/2013 | |
Nicole Onetto
BRD | Director/Board Member | 73 | 27/04/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 29/05/26 | Sell | -400 | 0.0030% | |||
| 13/05/26 | Sell | -1,043 | 0.0078% | |||
| 04/05/26 | Sell | 400 | 0.0030% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +4.39% | +46.96% | +60.28% | 104.07Cr | |
| +0.59% | +2.73% | +1.48% | +28.74% | 4.63TCr | |
| +0.55% | +0.87% | +42.67% | +34.54% | 4.39TCr | |
| +0.74% | -6.25% | +333.01% | +530.91% | 4.09TCr | |
| +4.01% | +3.26% | +8.16% | +94.58% | 3.99TCr | |
| +1.11% | +1.80% | +11.52% | +43.15% | 2.95TCr | |
| +1.89% | +4.60% | +25.04% | +158.63% | 1.71TCr | |
| +0.71% | -9.92% | - | - | 1.55TCr | |
| +2.12% | +8.18% | +24.54% | +41.21% | 1.52TCr | |
| -0.28% | +25.83% | -8.84% | - | 1.4TCr | |
| Average | +1.24% | +3.92% | +53.84% | +124.00% | 2.63TCr | |
| Weighted average by Cap. | +1.34% | +2.09% | +68.43% | +141.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 27Cr 33Cr 28Cr 24Cr 46Cr 3.13TCr 46Cr 320.88Cr 123.68Cr 1.59TCr 122.56Cr 119.85Cr 5.14TCr | 28Cr 34Cr 29Cr 25Cr 47Cr 3.21TCr 47Cr 329.55Cr 127.02Cr 1.64TCr 125.87Cr 123.08Cr 5.28TCr |
| Net income | 6.87Cr 8.37Cr 7.29Cr 6.26Cr 12Cr 801.44Cr 12Cr 82Cr 32Cr 408.25Cr 31Cr 31Cr 1.32TCr | 5.83Cr 7.1Cr 6.19Cr 5.31Cr 9.95Cr 680.16Cr 9.97Cr 70Cr 27Cr 346.47Cr 27Cr 26Cr 1.12TCr |
| Net Debt | -15Cr -19Cr -16Cr -14Cr -26Cr -1.78TCr -26Cr -182.87Cr -70Cr -907.46Cr -70Cr -68Cr -2.93TCr | -22Cr -27Cr -23Cr -20Cr -37Cr -2.54TCr -37Cr -260.95Cr -100.58Cr -1.29TCr -100Cr -97Cr -4.18TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/26/21 | CHF 69.00 | 0.00% | 35,900 |
| 18/26/18 | CHF 69.00 | 0.00% | 1,24,822 |
| 17/26/17 | CHF 69.00 | +3.76% | 87,077 |
| 16/26/16 | CHF 66.50 | +1.68% | 22,908 |
| 15/26/15 | CHF 65.40 | -1.06% | 34,306 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BSLN Stock
Select your edition
All financial news and data tailored to specific country editions
